[Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy].
Koharazawa H, Watanabe R, Hattori Y, Numata A, Kawasaki R, Kuwabara H, Hagihara M, Matsumoto K, Tanaka M, Hashimoto C, Takemura S, Yamazaki E, Fujimaki K, Taguchi J, Tomita N, Fujita H, Sakai R, Harano H, Ishigatsubo Y, Fujisawa S.
Koharazawa H, et al. Among authors: kuwabara h.
Rinsho Ketsueki. 2015 Apr;56(4):392-9. doi: 10.11406/rinketsu.56.392.
Rinsho Ketsueki. 2015.
PMID: 25971269
Japanese.